Potential conflicts of interest. H. F. C. reports support from Merck and has stock in Moderna and Merck (wife's individual retirement account); grants or contracts from the Antibacterial Resistance Leadership Group (UM1AI104681, National Institutes of Health/National Institute of Allergy and Infectious Diseases [NIAID]); royalties or licenses as editor of The Sanford Guide to Antimicrobial Therapy; payment for expert testimony to author from Nexus Pharmaceuticals (patent dispute) and Eli Lilly (product liability case); and participation on a data and safety monitoring board or advisory board for Merck. S. B. D. reports funding for clinical research studies from Gilead, Pfizer, F2G, Regeneron, Chan Zuckerberg Biohub, and NIAID; personal consulting fees from Genentech and Janssen/J + J; compensation for clinical events/committee participation from Shinogi, Basilea, and Duke Clinical Research Institute; support for travel to speak at IDWeek from the Infectious Diseases Society of America (IDSA); a patent (US20100143379A1) for Mif agonists and antagonist and therapeutic uses thereof; and a leadership or fiduciary role on the IDSA Antibacterial Resistance Committee, California Department of Public Health Hospital Acquired Infections Program (CADPH HAI) Advisory Committee, Antibacterial Resistance Leadership Group Innovations Group, Laboratory Center, Mentorship Committee, Gram Positive Committee, and Immunosuppressed Host Group. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.